Last reviewed 2026-06-10 · How we verify

Gastro-esophageal reflux disease with esophagitis — Treatment Landscape & Competitive Intelligence

Gastro-esophageal reflux disease with esophagitis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Gastro-esophageal reflux disease with esophagitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. · 3 drugs in Gastro-esophageal reflux disease with esophagitis
2. Genuine Research Center, Egypt · 1 drug in Gastro-esophageal reflux disease with esophagitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gastro-esophageal reflux disease with esophagitis:

• Gastro-esophageal reflux disease with esophagitis treatment updates — RSS
• Gastro-esophageal reflux disease with esophagitis treatment updates — Atom
• Gastro-esophageal reflux disease with esophagitis treatment updates — JSON

Cite this brief

Drug Landscape (2026). Gastro-esophageal reflux disease with esophagitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gastro-esophageal-reflux-disease-with-esophagitis. Accessed 2026-06-10.

Related

• Gastro-esophageal reflux disease with esophagitis full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing